GlassScriptPhysician profile
Jonathan T Turriago
NPI 1437413705
$2,490.14
in general payments reported to CMS, 2019-2025
29 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $105 · 2021: $235 · 2022: $774 · 2023: $473 · 2024: $104 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.57 | 2019-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $292.28 | 2021-2025 | |
| Exeltis, USA INC. | $211.92 | 2022-2025 | Slynd |
| Novo Nordisk INC | $147.12 | 2022-2025 | Wegovy |
| Becton, Dickinson and Company | $136.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.35 | 2019-2022 | |
| Astellas Pharma US INC | $125.69 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $82.56 | 2022 | |
| Pfizer INC. | $69.38 | 2023-2025 | |
| Sage Therapeutics, LLC | $67.76 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $57.81 | 2021-2022 | |
| Coopersurgical, INC. | $54.12 | 2019-2023 | Paragard T 380a |
| Scynexis, INC. | $46.96 | 2022 | |
| Baxter Healthcare | $42.42 | 2023 | Perclot |
| Amag Pharmaceuticals, INC. | $40.05 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $38.12 | 2023 | |
| Sumitomo Pharma America, INC. | $36.52 | 2023-2025 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $26.89 | 2019-2022 | |
| Organon LLC | $24.63 | 2021 | |
| Daiichi Sankyo INC. | $24.11 | 2022 | |
| Millicent US INC | $22.65 | 2025 | Femlyv, Intrarosa |
| Channel Medsystems, INC. | $22.25 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $20.99 | 2023 | Vivjoa |
| Hologic Sales and Service, LLC | $19.88 | 2022 | |
| Agile Therapeutics, INC. | $18.95 | 2023 | Twirla |
| Genzyme Corporation | $17.90 | 2019 | |
| Medicem INC. | $14.39 | 2022 | |
| Merck Sharp & Dohme LLC | $13.80 | 2019 | |
| Allergan, INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Turriago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.